Can a blood test predict the onset of Multiple Sclerosis?

In a recent discovery, UC San Francisco (UCSF) scientists have found a revolutionary method for identifying early biomarkers for multiple sclerosis (MS). MS is an autoimmune disease that attacks the myelin surrounding the nerves in the central nervous system, affecting the brain and spinal cord. Like many other autoimmune diseases, there is currently no cure for MS.

Researchers at UCSF found that some MS patients had a distinct set of autoantibodies in their blood years before the onset of symptoms. These autoantibodies were observed to bind not only to human cells but also to common pathogens, suggesting a potential link between certain viral or bacterial infections and the development of MS.

The study highlights the potential of detecting these autoantibodies through a simple blood test, enabling early intervention and treatment for MS patients. The test utilizes an advanced blood screening method called phage display immunoprecipitation sequencing (PhIP-Seq), and allows researchers to identify autoantibodies against a wide range of human proteins.

By comparing blood samples from 250 MS patients and 250 healthy veterans, UCSF researchers found that 10% of the MS patients had a significantly higher amount of autoantibodies years before their diagnosis. The research team's findings were further validated by analyzing blood samples from patients enrolled in the UCSF ORIGINS study, where the same autoantibody pattern was observed in 10% of individuals diagnosed with MS, providing a potential diagnostic marker for the disease. While many questions about MS remain unanswered, this study represents a significant step forward for more effective diagnosis, early intervention, and better treatment for this debilitating neurological condition.

To support the Autoimmune Registry, please share our information with others with autoimmune diseases. Donations are also greatly appreciated!